Next Phase Newsletter

A life sciences venture capital fund founded in 2014 with a base in the Asia Pacific region currently manages two funds with $330 million assets under management and is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

The firm is focused on Therapeutics and Medical Devices opportunities. The firm’s core focused therapeutic areas include oncology, immunology and CNS diseases, but is also opportunistic in other indications (modality agnostic) and willing to consider orphan indications. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular diseases.

The firm prefers management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new venture fund, founded in 2019, based in the East Coast, is focused on investing in digital health technologies, with a secondary focus on enterprise software. The firm will consider all digital health companies, but has a particular interest in novel applications. The fund will invest between $50,000-1M in companies with a pre-money valuation of $2-12M, with some money reserved for follow-on investments. The firm will invest only in companies based in the US.

The firm is willing to consider all types of digital health technologies but is primarily focused on software and technology enabled services. The fund is most interested in products/services that address unmet needs and offer novel solutions, as opposed to those that are improving on products that already exist. For solutions that appear incremental, The firm applies a higher standard in terms of market validation and evidence of a repeatable sales process.

The firm looks to invest in companies with a pre-money valuation of no greater than 12M.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm with offices in USA and China consists of limited partners who include institutional investors from US and China. Typical equity investments range from US$5-10 million in businesses from Series A to pre-IPO and publicly traded companies. The firm is open to leading or following a syndicated round. Good Health Capital is now focusing on opportunities in North America.

The firm invests across therapeutics, medical devices, diagnostics, platform technologies, and digital health and is looking for companies that are top 3 in their niche sector. Within therapeutics, the firm prefer clinical stage projects. The firm is opportunistic in terms of disease areas including orphan indications. Within device and diagnostics, the firm prefers post-prototype products with clinical validation.

The firm may request board representation or board observership on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and Japan, generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 90% of its capital in the USA, Japan and Israel, with the remaining 10% open to global opportunities.

The firm invests in advanced therapeutics, digital health, novel (sensor based IoT) devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. The firm prefers to invest in technologies at an early stage of development.

The firm is interested in working with high-quality management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A real estate company / family office investment vehicle based in North America is looking to expand their investments into the healthcare field. The firm is looking to invest $4-5 million into various startups in the upcoming year, seeking opportunities at the Seed to Series A range. The firm is willing to both lead and follow on investments they make and are looking for opportunities solely within the USA and Canada.

The firm is looking for opportunities within the Medical Device, Digital Health, Diagnostics, and Biotech R&D Spaces. Specifically, the firm is looking for technologies that can help physicians. Examples of such technologies include: telemedicine, clinical trial services for physicians, and digital health solutions to help patient engagement. The firm is also interested in new medical devices and diagnostic technologies that are in the clinical trial stage. The firm is currently not interested in therapeutics.

The firm is looking for a strong management team who has a strong vision and development plan for the technology of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based venture firm is focused on pre-seed and seed stage investments, typically with an initially investment of $500k to $1m as part of the company’s first institutional funding. The firm prefers companies located in the US and Canada. The firm will make 5-10 new investments over the next 12 months.

The firm partners with entrepreneurs solving real-world problems with data and machine learning, focusing on applications of frontier technologies such as AI, computational biotech, connected sensors, AR/VR, and blockchain. Past investments include biomedical and genomics data analytics platforms, data and analysis tools for drug discovery, and related areas.

The firm desires experienced management teams with a vision for the future. The firm can take a board seat when they have specific expertise in the area, and does not have an equity target. Strong technical teams who have a deep understanding of their markets is desired, though they’re comfortable partnering with very early-stage (pre-product) companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An evergreen fund based in Western Europe with LPs who were successful dot-com entrepreneurs is a hands-on investor in early-stage companies, historically in the tech sector but the firm now also invests in the life science space. The firm’s investments are generally EUR 3-5 million and are focused on Southeast Europe. The firm has successfully invested in over 60 companies.

The firm is opportunistic in the life science and healthcare tech space but prefers market evaluation with business models focused on B2B; previous investments include bio-informatic technologies and point of care diagnostics. The firm will consider opportunities in any indication area and is open to investing in technologies at an early development stage, prior to regulatory approval.

The firm has a management team with a very hands-on approach and often makes majority investments. The firm generally does not tranche its financings.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.